← Back to Clinical Trials
Recruiting Phase 1 NCT02889666

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

Trial Parameters

Condition Recurrent Non-small Cell Lung Cancer
Sponsor Shanghai Jiao Tong University School of Medicine
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 500
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2008-01
Completion 2026-12
Interventions
CisplatinCarboplatinDocetaxel

Brief Summary

The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.

Eligibility Criteria

Inclusion Criteria: * Age ≤ 75 years with histologically proven NSCLC * No severe major organ dysfunction * WHO performance status of 0 or 1 * No prior cancer chemotherapy * A Clinical Stage ≥ IA (T1a, N0, M0) of lung disease but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer TNM staging system) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan. Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy * Stage IV

Related Trials